HC seeks replies on plea to speed up Ranitidine safety review

The court is examining a plea that seeks a time-bound conclusion to India’s unresolved Ranitidine safety review. The request is directed at the Centre and its drug regulatory authorities. The issue matters because Ranitidine is widely used, inexpensive and often purchased without a prescription.

The bench issued notice to the Centre, CDSCO, DTAB and ICMR. The petition says DTAB referred the matter to another committee and an ICMR study on April 24, 2025. A three-month reporting deadline fixed on July 24, 2025, reportedly expired around October 24, 2025.

Yet CDSCO said on October 7, 2026, that the report was still awaited and the matter remained under review. The court will hear the matter again in February. The plea seeks a clear, reasoned and publicly available decision, rather than an open-ended review.

Ranitidine is a medicine commonly used to treat acidity. It also reduces the amount of acid in the stomach. The article presents it as cheap, widely available and often bought without a prescription, giving the safety question broad public importance.

The article does not explain the medicine’s biological mechanism in detail. In general, Ranitidine reduces stomach acid by blocking signals that stimulate acid production in stomach cells. This can help relieve acid-related symptoms, but the article focuses on the medicine’s unresolved safety assessment rather than its treatment benefits.

The concern began after foreign regulators were alerted to NDMA in products containing Ranitidine in September 2019. India’s regulator has examined the issue for years, but the petition alleges that no final, reasoned and public decision has been disclosed. The court has now sought replies and will hear the case again in February.

NDMA stands for N-nitrosodimethylamine. The article describes it as a probable human carcinogen, meaning a substance considered capable of causing cancer in people. Its possible presence in a widely used medicine creates a serious reason for regulators to examine product safety.

Foreign drug regulators were alerted to NDMA in Ranitidine-containing products in September 2019. In general, regulators investigate such concerns by testing medicines, assessing the level and consistency of contamination, and comparing possible risks with treatment benefits. The article does not provide test results or a specific risk level for Ranitidine.

The United States, European Union and Australia took regulatory action in 2020 under different legal frameworks. The petition says India has not disclosed a final, reasoned or publicly available decision. The Delhi high court is seeking replies while the review remains pending, with the next hearing scheduled for February.

The concern began in September 2019, when foreign regulators were alerted to NDMA in products containing Ranitidine. By October 2026, the matter had remained unresolved in India for more than seven years. The petition says India’s regulator still had not disclosed a final, reasoned and publicly available decision.

The petition identifies six jurisdictions that reached some decision after the alerts: the United States, the European Union, Australia, Canada, the United Kingdom and Singapore. It also says the United States, European Union and Australia took regulatory action in 2020, using different legal frameworks.

India’s review continued through DTAB, another committee and an ICMR study. A three-month deadline set in July 2025 expired around October 24, 2025, but CDSCO said on October 7, 2026, that the report was awaited. The court is considering whether a fixed timetable is needed.

A prolonged review can leave patients, doctors and sellers without a clear public answer about whether a medicine should continue being used. The article does not establish that Ranitidine is causing harm in India. It does show that the possible NDMA concern remains unresolved and that no final public decision has been disclosed.

Ranitidine is described as cheap, widely available and often bought without a prescription. If uncertainty continues, people may keep buying or using it without knowing what decision regulators have reached. The petition says those carrying the burden are often least able to find or pay for alternative care.

The practical consequence is continued uncertainty rather than a confirmed medical outcome. A clear decision could explain whether the medicine should remain available, face restrictions or be withdrawn. The court has sought replies and will hear the matter again in February, while CDSCO says its report is still awaited.

The article identifies four bodies involved in India’s review. CDSCO is the country’s drug regulator. DTAB is the technical advisory body that referred the matter to a further committee and an ICMR study. ICMR is involved through that study, while the Union government set a three-month deadline for the report.

The timeline shows how their roles connected. DTAB referred the issue on April 24, 2025. The Union government fixed the reporting deadline on July 24, 2025. Around October 24, the three-month period expired. CDSCO nevertheless said on October 7, 2026, that the report was awaited and the matter remained under review.

These roles describe the process reported in the article, not a completed decision. The petition asks the court to require a stipulated timetable and a final, reasoned, public outcome. The court has sought replies from all four bodies and the next hearing is in February.

A regulator investigating a possible carcinogen usually begins by confirming whether the substance is present and measuring its level across medicines and batches. It then assesses exposure, possible health effects, manufacturing causes and the medicine’s benefits. The goal is to determine whether the risk is acceptable and what action protects patients.

Possible outcomes include continued sale with monitoring, restrictions, warnings, recalls or withdrawal. The appropriate step depends on the evidence and the balance between risk and medical need. The article specifically says foreign regulators in the United States, European Union, Australia, Canada, the United Kingdom and Singapore reached some decision after the 2019 alerts.

In India, DTAB referred the matter to another committee and an ICMR study. The deadline set by the Union government expired around October 24, 2025. CDSCO said on October 7, 2026, that the report was still awaited, so the article does not describe a completed Indian risk decision.